Home › Core › ISCC-IDs › 28CCh4MLt6Xmf

View ISCC-ID

Core Data

28CCh4MLt6Xmf
ISCC-ID - digital asset identifier
CCDh4RnyuMo5V-CT4nvgr8x94BD-CDrjsYLahKrAp-CRaH3Xwf4rW5J
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

do low to middleincome countries need a biosimilar approval pathway based on a full comparability exercise

Ledger Reference

coblo
Source Ledger/Blockchain
12405475
N-th ISCC Decleration on source ledger
500e6444206b2505883a37fbcd9ad237d4af331ede8ac993a0dc4ebbd6d3b39a
Hash of block that includes the ISCC-DECLARATION
9928dae97a1835325fc37f3202b2fba217c31bc37df8905eb17bb1fd19dd93c9
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "Do low- to middle-income countries need a biosimilar approval pathway based on a full comparability exercise?", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Armando A Genazzani", "@type": "Person"}, {"name": "Nicola Magrini", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "http://gabi-journal.net/wp-content/uploads/GJ-2013-4-p163-164-Editorial-Genazzani.pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "Pro Pharma Communications International", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.5639/gabij.2013.0204.044", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCDh4RnyuMo5V-CT4nvgr8x94BD-CDrjsYLahKrAp-CRaH3Xwf4rW5J", "propertyID": "ISCC"}], "datePublished": "2013-12-15"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close